Beyond Air, Inc. (XAIR) Submits Premarket Approval Application to FDA for LungFit PH to Treat Persistent Pulmonary Hypertension of the Newborn

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. NVDA
6. IBM
7. PRIM
8. SPY
9. ACN
10. BLZE

Go back to Beyond Air, Inc. (XAIR) Submits Premarket Approval Application to FDA for LungFit PH to Treat Persistent Pulmonary Hypertension of the Newborn

Beyond Air® Submits Premarket Approval Application to FDA for LungFit™ PH to Treat Persistent Pulmonary Hypertension of the Newborn

November 11, 2020 7:30 AM EST

Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating improved economics and safety in hospital setting

Will be subject to a 180-day review period by the FDA

Launch expected in 2Q 2021, pending approval

GARDEN CITY, N.Y., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory... More